Does pharma money change how doctors prescribe?

What the research actually shows, including the strongest arguments on both sides.

This is the question underneath every search on this site, so it deserves a straight answer rather than an implication.

What the evidence shows

Multiple large observational studies, several using Open Payments data itself, have found an association between receiving industry payments and prescribing the paying company’s product. The association shows up even at very small values — studies of Medicare Part D prescribing have found measurable differences among physicians who received a single meal worth under $20.

The effect appears dose-responsive: more meals, more prescribing of the branded drug; higher-value payments, larger differences. It has been reproduced across drug classes and specialties.

What the evidence does not show

Almost all of this work is observational. It establishes correlation with reasonable consistency; it does not establish that the payment caused the prescribing. The obvious confound is real and rarely eliminated: representatives target physicians who already prescribe heavily in a category, and physicians who are enthusiastic about a new drug are more likely to accept an invitation to hear about it. Causation could run either way, or both.

The strongest case for concern

The size of the association at trivial payment values is hard to explain away by targeting alone. Reciprocity is one of the best-documented effects in social psychology, it operates below conscious awareness, and physicians consistently rate themselves as less susceptible to it than their colleagues — which is itself a well-known warning sign.

The strongest case against reading too much into it

Industry funds most clinical education, most trials, and nearly all device innovation. A physician who consults for a manufacturer may be the person best placed to improve the product. Royalty income means someone invented something patients use. Framing all of this as capture confuses marketing spend with the ordinary infrastructure of medicine — and a physician who has never spoken to industry is not automatically a better clinician.

What to do with a profile you have looked up

Treat it as context, not verdict. If your doctor has a large speaking or consulting relationship with the maker of a drug they just prescribed you, that is a fair and civil thing to ask about. Most will answer readily. A record of meals is not worth raising.